Shares of Antares Pharma, Inc. (NASDAQ:ATRS) have been given an average recommendation of “Buy” by the six research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and two have given a strong buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $3.84.

A number of brokerages have weighed in on ATRS. HC Wainwright set a $5.00 price target on shares of Antares Pharma and gave the company a “buy” rating in a report on Friday, October 13th. Vetr lowered shares of Antares Pharma from a “buy” rating to a “hold” rating and set a $3.42 price target on the stock. in a report on Wednesday, July 12th. Piper Jaffray Companies set a $4.00 price target on shares of Antares Pharma and gave the company a “buy” rating in a report on Wednesday, July 26th. Finally, ValuEngine lowered shares of Antares Pharma from a “hold” rating to a “sell” rating in a report on Monday, October 16th.

Shares of Antares Pharma (NASDAQ:ATRS) opened at 1.92 on Friday. The firm has a 50-day moving average price of $2.92 and a 200-day moving average price of $2.95. The stock’s market cap is $300.30 million. Antares Pharma has a 12 month low of $1.41 and a 12 month high of $4.09.

Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.01. The company had revenue of $13.42 million for the quarter, compared to analyst estimates of $12.99 million. Antares Pharma had a negative net margin of 34.27% and a negative return on equity of 41.37%. Equities analysts expect that Antares Pharma will post ($0.10) EPS for the current fiscal year.

In other news, Director Thomas J. Garrity sold 30,000 shares of the firm’s stock in a transaction on Tuesday, October 3rd. The shares were sold at an average price of $3.50, for a total value of $105,000.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Leonard S. Jacob sold 230,000 shares of the firm’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $4.05, for a total transaction of $931,500.00. The disclosure for this sale can be found here. Company insiders own 11.60% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Antares Pharma by 10.1% in the 2nd quarter. Vanguard Group Inc. now owns 6,186,232 shares of the specialty pharmaceutical company’s stock valued at $19,920,000 after acquiring an additional 567,144 shares during the period. Rubric Capital Management LP raised its stake in shares of Antares Pharma by 34.4% in the 2nd quarter. Rubric Capital Management LP now owns 3,188,600 shares of the specialty pharmaceutical company’s stock valued at $10,267,000 after acquiring an additional 816,630 shares during the period. Renaissance Technologies LLC raised its stake in shares of Antares Pharma by 10.3% in the 1st quarter. Renaissance Technologies LLC now owns 3,152,569 shares of the specialty pharmaceutical company’s stock valued at $8,953,000 after acquiring an additional 293,228 shares during the period. State Street Corp raised its stake in shares of Antares Pharma by 2,682.1% in the 2nd quarter. State Street Corp now owns 2,027,650 shares of the specialty pharmaceutical company’s stock valued at $6,530,000 after acquiring an additional 1,954,769 shares during the period. Finally, JW Asset Management LLC raised its stake in shares of Antares Pharma by 27.7% in the 2nd quarter. JW Asset Management LLC now owns 1,671,956 shares of the specialty pharmaceutical company’s stock valued at $5,384,000 after acquiring an additional 362,431 shares during the period. 36.76% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Antares Pharma, Inc. (ATRS) Receives Average Rating of “Buy” from Analysts” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/29/antares-pharma-inc-atrs-receives-average-rating-of-buy-from-analysts.html.

About Antares Pharma

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.